CTCL
MCID: CTN015
MIFTS: 50

Cutaneous T Cell Lymphoma (CTCL) malady

Categories: Rare diseases, Cancer diseases, Immune diseases, Skin diseases, Blood diseases

Aliases & Classifications for Cutaneous T Cell Lymphoma

Aliases & Descriptions for Cutaneous T Cell Lymphoma:

Name: Cutaneous T Cell Lymphoma 12 14
Lymphoma, T-Cell, Cutaneous 42 69
Cutaneous T-Cell Lymphoma 12 50
Lymphoma T-Cell Cutaneous 52
Ctcl 50

Classifications:



External Ids:

Disease Ontology 12 DOID:0060061
MeSH 42 D016410

Summaries for Cutaneous T Cell Lymphoma

NIH Rare Diseases : 50 cutaneous t-cell lymphomas (ctcls) are a group of disorders characterized by an abnormal accumulation of cancerous t-cells (a type of white blood cells) in the skin resulting in an itchy, red rash that can thicken or form a tumor. ctcls belong to a larger group of disorders known asnon-hodgkin's lymphomas. the most common types are mycosis fungoides and sézary syndrome. in some cases, cancerous t-cells may spread to the lymph nodes and eventually to other body tissues and organs, potentially resulting in life-threatening complications. the specific signs and symptoms vary from person to person. the exact cause of these conditions is unknown. last updated: 9/27/2011

MalaCards based summary : Cutaneous T Cell Lymphoma, also known as lymphoma, t-cell, cutaneous, is related to mycosis fungoides and parapsoriasis. An important gene associated with Cutaneous T Cell Lymphoma is CTAGE1 (Cutaneous T-Cell Lymphoma-Associated Antigen 1), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs Istodax and Targretin have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and lymph node, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin's lymphoma that has material basis in a mutation of T cells.

Related Diseases for Cutaneous T Cell Lymphoma

Diseases in the Cutaneous T Cell Lymphoma family:

Primary Cutaneous Gamma/delta-Positive T-Cell Lymphoma

Diseases related to Cutaneous T Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 149)
id Related Disease Score Top Affiliating Genes
1 mycosis fungoides 11.6
2 parapsoriasis 11.3
3 lymphoma 11.1
4 sezary's disease 11.0
5 granulomatous slack skin disease 11.0
6 dermatitis 10.2
7 acute myocarditis 10.2 IL15 IL2
8 asymptomatic neurosyphilis 10.2 IFNG IL2RA
9 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.2 IFNG IL2 IL2RA
10 parametritis 10.2 IFNG IL2 IL2RA
11 cyclosporiasis 10.2 IFNG IL2 IL2RA
12 paralytic poliomyelitis 10.2 IFNG IL2
13 lymphomatoid papulosis 10.2
14 central nervous system origin vertigo 10.2 IFNG IL2 IL2RA
15 myiasis 10.2 IFNG IL2 IL2RA
16 caplan's syndrome 10.2 IFNG IL2
17 heart conduction disease 10.2 IFNG IL2 IL2RA
18 ectopic thymus 10.2 IL15 IL2 IL7
19 causalgia 10.1 IFNG IL2 IL2RA
20 retinal ischemia 10.1 IFNG IL2 IL2RA
21 autosomal dominant deafness-onychodystrophy syndrome 10.1 IFNG IL2
22 hemoglobinopathy 10.1 IFNA1 IL2 IL2RA
23 subungual glomus tumor 10.1 GZMB IFNG
24 leukemia 10.1
25 scleral disease 10.1 IFNG IL2 IL2RA
26 anterior foramen magnum meningioma 10.1 IFNA1 IFNG IL2 IL2RA
27 venezuelan hemorrhagic fever 10.1 GZMB IFNG IL2
28 squamous cell papilloma of skin 10.1 IL15 IL2 IL2RA IL7
29 exophthalmos 10.1 IFNA1 IFNG IL15 IL2
30 goodpasture syndrome 10.0 IFNA1 IFNG IL2 IL2RA
31 anus leiomyosarcoma 10.0 IFNA1 IFNG IL2 IL7
32 red cell phospholipid defect with hemolysis 10.0 GZMB IFNG IL15
33 advanced sleep phase syndrome, familial, 1 10.0 IFNA1 IFNG IL2 IL2RA
34 prostatic urethral cancer 10.0 IFNG IL2 IL2RA IL7
35 atopic dermatitis 10.0
36 pityriasis lichenoides 10.0
37 alcoholic liver cirrhosis 10.0 IL2 IL2RA TNFRSF8
38 t-cell leukemia 10.0
39 hydroa vacciniforme 10.0
40 acute myeloid leukemia with recurrent genetic anomaly 10.0 GZMB IFNG IL2 IL2RA
41 periodontosis 10.0 GZMB IFNG IL2 IL2RA
42 adult t-cell leukemia 9.9
43 psoriasis 9.9
44 alström syndrome 9.9 GZMB TIA1
45 hemophagocytic lymphohistiocytosis 9.9 HDAC9 IL2 IL2RA TNFRSF8
46 malignant glioma 9.9 GZMB IFNA1 TIA1
47 follicular mucinosis 9.9
48 chronic graft versus host disease 9.9
49 pyoderma gangrenosum 9.9
50 chronic actinic dermatitis 9.9

Graphical network of the top 20 diseases related to Cutaneous T Cell Lymphoma:



Diseases related to Cutaneous T Cell Lymphoma

Symptoms & Phenotypes for Cutaneous T Cell Lymphoma

MGI Mouse Phenotypes related to Cutaneous T Cell Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCR4 HSD17B11 IFNG IL15 IL2 IL2RA
2 immune system MP:0005387 9.32 IL7 TGFBR1 TIA1 TNFRSF8 CCR4 HSD17B11

Drugs & Therapeutics for Cutaneous T Cell Lymphoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Istodax 17 46 ROMIDEPSIN Gloucester Pharmaceuticals Approved November 2009
2
Targretin 17 46 bexarotene VALEANT LUXEMBOURG 12/29/1999
3
UVADEX 17 METHOXSALEN Therakos Approved February 1999
4
Valchlor 17 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics Approved August 2013

Drugs for Cutaneous T Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 437)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 153559-49-0 82146
2
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1 298-81-7 4114
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
4
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1 173146-27-5
5
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
6
Fosaprepitant Approved Phase 4 172673-20-0 219090
7
Vorinostat Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 149647-78-9 5311
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 59-30-3 6037
9
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
10
Substance P Investigational Phase 4 33507-63-0 44359816
11 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
12 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
13 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
16 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
17 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
19 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Vitamin B Complex Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
23 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
24 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Histone Deacetylase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
29 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
30 Interferon-alpha Phase 4,Phase 2
31 interferons Phase 4,Phase 2,Phase 1,Early Phase 1
32 neurokinin A Phase 4
33 Neurokinin-1 Receptor Antagonists Phase 4
34 Clorazepate Dipotassium Phase 4
35 Folate Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
36 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
37
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
38
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
39
Ofloxacin Approved Phase 3 82419-36-1 4583
40
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
41
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
42
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
43
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
44
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
45
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 55-98-1 2478
46
Etoposide Approved Phase 2, Phase 3, Phase 1, Early Phase 1 33419-42-0 36462
47
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
48
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
49
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
50
Lenalidomide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 191732-72-6 216326

Interventional clinical trials:

(show top 50) (show all 525)
id Name Status NCT ID Phase
1 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4
2 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4
3 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4
4 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4
5 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4
6 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Recruiting NCT01569724 Phase 4
7 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4
8 PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides Terminated NCT00630903 Phase 4
9 Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Terminated NCT01625455 Phase 4
10 Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study Withdrawn NCT01801670 Phase 4
11 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
12 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
13 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
14 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3
15 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Completed NCT00490776 Phase 2, Phase 3
16 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
17 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
18 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
19 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
20 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
21 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
22 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
23 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
24 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
25 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
26 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
27 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
28 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
29 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
30 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
31 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
32 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
33 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
34 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
35 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
36 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
37 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
38 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Recruiting NCT01871727 Phase 3
39 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Recruiting NCT02448381 Phase 3
40 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With Mycosis Fungoides (MF) Form of CTCL Recruiting NCT02811783 Phase 3
41 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Active, not recruiting NCT01578499 Phase 3
42 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Active, not recruiting NCT01728805 Phase 3
43 PUVA Maintenance Therapy in Mycosis Fungoides Active, not recruiting NCT01686594 Phase 3
44 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
45 Lenalidomide Maintenance Post-debulking in Advanced CTCL Terminated NCT01098656 Phase 3
46 Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Terminated NCT00127881 Phase 3
47 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3
48 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3
49 Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3
50 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma Withdrawn NCT01386398 Phase 3

Search NIH Clinical Center for Cutaneous T Cell Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: lymphoma, t-cell, cutaneous

Genetic Tests for Cutaneous T Cell Lymphoma

Anatomical Context for Cutaneous T Cell Lymphoma

MalaCards organs/tissues related to Cutaneous T Cell Lymphoma:

39
T Cells, Skin, Lymph Node, B Cells, Thyroid, Neutrophil, Bone

Publications for Cutaneous T Cell Lymphoma

Articles related to Cutaneous T Cell Lymphoma:

(show top 50) (show all 838)
id Title Authors Year
1
miR-155 expression in Primary Cutaneous T-Cell Lymphomas (CTCL). ( 26935979 )
2017
2
Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells. ( 27929746 )
2017
3
Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. ( 27521316 )
2016
4
Intrahepatic Xenograft of Cutaneous T-Cell Lymphoma Cell Lines: A Useful Model for Rapid Biological and Therapeutic Evaluation. ( 27181405 )
2016
5
Hydroa Vacciniforme-Like EBV-Positive Cutaneous T-Cell Lymphoma, First Report of 2 Cases in Ecuador. ( 26913846 )
2016
6
Histology Resembling Cutaneous T-Cell Lymphoma in Nodular Scabies: A Case Report. ( 26955156 )
2016
7
Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T cell lymphoma. ( 27634769 )
2016
8
Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial. ( 27007550 )
2016
9
Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma. ( 27181628 )
2016
10
Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside. ( 27262707 )
2016
11
Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma. ( 27054291 )
2016
12
Gelling Your Dermatology Nursing Practice: A Practical Guide for Managing the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel. ( 28529678 )
2016
13
Lymphocytes from patients with cutaneous T-cell lymphoma show DNA instability and reduced DNA repair using the Comet assay. ( 27878874 )
2016
14
Differential NFATc1 Expression in Primary Cutaneous CD4+ Small/Medium-Sized Pleomorphic T-Cell Lymphoma and Other Forms of Cutaneous T-Cell Lymphoma and Pseudolymphoma. ( 27097342 )
2016
15
Primary Cutaneous T Cell Lymphoma (Gamma Delta subtype). ( 28064300 )
2016
16
The role of polymorphism of interleukin-2, -10, -13 and TNF-I+ genes in cutaneous T-cell lymphoma pathogenesis. ( 28035219 )
2016
17
Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma. ( 27351221 )
2016
18
The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma. ( 26802931 )
2016
19
STAT5 induces miR-21 expression in cutaneous T cell lymphoma. ( 27329723 )
2016
20
The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines. ( 27002643 )
2016
21
Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. ( 27422033 )
2016
22
Inactivation of RUNX3/p46 Promotes Cutaneous T-Cell Lymphoma. ( 27377697 )
2016
23
75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma. ( 27741338 )
2016
24
Primary Cutaneous T-cell Lymphoma with Aberrant Expression of CD20. ( 27840885 )
2016
25
Pagetoid reticulosis (epitheliotropic cutaneous T-cell lymphoma) in an adult alpaca (Vicugna pacos). ( 27154316 )
2016
26
Cutaneous T-cell lymphoma in a patient with celiac disease. ( 27529713 )
2016
27
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? ( 27998183 )
2016
28
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. ( 27935859 )
2016
29
Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. ( 26923912 )
2016
30
Latest insights into pathogenesis of mycosis fungoides/cutaneous T-cell lymphoma. ( 27982549 )
2016
31
Erratum to: Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review. ( 27747468 )
2016
32
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. ( 26738536 )
2016
33
Systematic Review of Cases of Cutaneous T-Cell Lymphoma Transformation in Pityriasis Lichenoides and Small Plaque Parapsoriasis. ( 27031678 )
2016
34
Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/SAczary syndrome): Use in a community setting. ( 27637355 )
2016
35
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. ( 27247757 )
2016
36
Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma. ( 27821903 )
2016
37
Cutaneous T-cell Lymphoma Metastatic to the Retina. ( 27012697 )
2016
38
Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma. ( 27144517 )
2016
39
An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case-control study. ( 27613059 )
2016
40
CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation. ( 27085537 )
2016
41
An Elderly Man With New Skin Plaques Consistent With Cutaneous T-Cell Lymphoma. ( 27744647 )
2016
42
(S039) Patterns of Care and Outcomes Among Patients Diagnosed With Cutaneous T-Cell Lymphoma (CTCL). ( 27083641 )
2016
43
Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review. ( 27590615 )
2016
44
Cutaneous T-Cell Lymphoma Misdiagnosed as Lipodermatosclerosis. ( 26914225 )
2016
45
Cutaneous T-Cell Lymphoma. A hypothesis on disease pathophysiology involving deficiency in DNA repair. ( 27501224 )
2016
46
Image Gallery: Cutaneous T-cell lymphoma mimicking a gyrate erythema. ( 27206367 )
2016
47
Cutaneous T-cell lymphoma. ( 27728561 )
2016
48
Cutaneous T-Cell Lymphoma and Pruritus: the Expression of IL-31 and its Receptors in the Skin. ( 27001482 )
2016
49
Lymph node image-guided core-needle biopsy for cutaneous T-cell lymphoma staging. ( 27377879 )
2016
50
Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. ( 27717961 )
2016

Variations for Cutaneous T Cell Lymphoma

Cosmic variations for Cutaneous T Cell Lymphoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM532 KRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,cutaneous T cell lymphoma c.38G>A p.G13D 5

Copy number variations for Cutaneous T Cell Lymphoma from CNVD:

7 (show all 49)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21732 1 16100000 20300000 Amplification Cutaneous T-cell lymphoma
2 25426 1 189000000 192100000 Deletion Cutaneous T-cell lymphoma
3 38869 10 105700000 111800000 Deletion Cutaneous T-cell lymphoma
4 39996 10 12300000 17300000 Deletion Cutaneous T-cell lymphoma
5 41377 10 17300000 19900000 Amplification Cutaneous T-cell lymphoma
6 42285 10 31400000 34500000 Deletion Cutaneous T-cell lymphoma
7 47113 10 89600000 92900000 Deletion PTEN Cutaneous T-cell lymphoma
8 61605 12 10000000 12600000 Deletion ETV6 Cutaneous T-cell lymphoma
9 71417 12 69800000 74100000 Deletion Cutaneous T-cell lymphoma
10 77639 13 46200000 48900000 Deletion RB1 Cutaneous T-cell lymphoma
11 83022 14 19100000 23600000 Deletion NDRG2 Cutaneous T-cell lymphoma
12 83023 14 19100000 23600000 Deletion ZNF219 Cutaneous T-cell lymphoma
13 97437 16 10300000 12500000 Deletion Cutaneous T-cell lymphoma
14 98274 16 16700000 20500000 Deletion Cutaneous T-cell lymphoma
15 107006 17 11200000 15900000 Deletion MAP2K4 Cutaneous T-cell lymphoma
16 108845 17 23200000 28800000 Amplification DHRS13 Cutaneous T-cell lymphoma
17 108846 17 23200000 28800000 Amplification ERAL1 Cutaneous T-cell lymphoma
18 108847 17 23200000 28800000 Amplification FLOT2 Cutaneous T-cell lymphoma
19 108848 17 23200000 28800000 Amplification PHF12 Cutaneous T-cell lymphoma
20 112029 17 37800000 41900000 Amplification Cutaneous T-cell lymphoma
21 116538 17 6800000 11200000 Deletion TP53 Cutaneous T-cell lymphoma
22 120627 18 2900000 7200000 Amplification Cutaneous T-cell lymphoma
23 123359 18 71300000 76117153 Deletion PARD6G Cutaneous T-cell lymphoma
24 133686 19 6900000 12600000 Deletion Cutaneous T-cell lymphoma
25 142291 2 221300000 224900000 Deletion Cutaneous T-cell lymphoma
26 152036 20 28400000 31500000 Amplification BCL2L1 Cutaneous T-cell lymphoma
27 162458 22 21800000 24300000 Amplification Cutaneous T-cell lymphoma
28 162461 22 21800000 24300000 Deletion Cutaneous T-cell lymphoma
29 171538 3 169200000 172500000 Amplification PRKCI Cutaneous T-cell lymphoma
30 180261 4 102500000 107900000 Amplification Cutaneous T-cell lymphoma
31 180582 4 107900000 114100000 Amplification Cutaneous T-cell lymphoma
32 181002 4 114100000 120600000 Amplification Cutaneous T-cell lymphoma
33 184833 4 182600000 187300000 Deletion Cutaneous T-cell lymphoma
34 186902 4 40900000 45600000 Deletion Cutaneous T-cell lymphoma
35 190065 4 82600000 84300000 Deletion Cutaneous T-cell lymphoma
36 203973 6 104800000 113900000 Deletion Cutaneous T-cell lymphoma
37 206027 6 135200000 139100000 Deletion Cutaneous T-cell lymphoma
38 211016 6 31900000 33600000 Deletion Cutaneous T-cell lymphoma
39 212690 6 40600000 45200000 Deletion VEGFA Cutaneous T-cell lymphoma
40 222425 7 15200000 19500000 Deletion Cutaneous T-cell lymphoma
41 225996 7 53900000 57400000 Amplification EGFR Cutaneous T-cell lymphoma
42 233736 8 127300000 131500000 Amplification MYC Cutaneous T-cell lymphoma
43 237881 8 27400000 29700000 Deletion Cutaneous T-cell lymphoma
44 238080 8 29700000 38500000 Deletion Cutaneous T-cell lymphoma
45 239603 8 39900000 43200000 Deletion Cutaneous T-cell lymphoma
46 243701 8 87200000 93500000 Amplification Cutaneous T-cell lymphoma
47 244139 8 93500000 99100000 Deletion Cutaneous T-cell lymphoma
48 249980 9 19900000 25500000 Deletion CDKN2A Cutaneous T-cell lymphoma
49 255727 9 83400000 86100000 Deletion Cutaneous T-cell lymphoma

Expression for Cutaneous T Cell Lymphoma

Search GEO for disease gene expression data for Cutaneous T Cell Lymphoma.

Pathways for Cutaneous T Cell Lymphoma

Pathways related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.47 CCR4 HDAC9 IFNA1 IFNG IL15 IL2
2
Show member pathways
13.3 CCR4 IL15 IL2 IL2RA IL7 TGFBR1
3
Show member pathways
13.25 IFNA1 IFNG IL15 IL2 IL2RA IL7
4
Show member pathways
13.18 CCR4 IL15 IL2 IL2RA IL7 TGFBR1
5
Show member pathways
12.74 GZMB IFNA1 IFNG IL15 IL2 IL2RA
6
Show member pathways
12.67 IFNA1 IFNG IL15 IL2 IL2RA
7 12.44 GZMB IFNA1 IFNG IL2 IL2RA
8
Show member pathways
12.4 GZMB IFNA1 IFNG IL2
9 12.3 IL15 IL2 IL2RA TGFBR1
10
Show member pathways
12.05 IFNA1 IFNG IL15 IL2
11
Show member pathways
11.87 IFNA1 IFNG IL15 IL2 IL2RA IL7
12
Show member pathways
11.83 GZMB IFNG IL2 IL2RA
13
Show member pathways
11.79 GZMB IFNG TGFBR1
14 11.79 IFNG IL15 IL2 IL2RA IL7
15
Show member pathways
11.63 IFNG IL2 IL2RA
16 11.53 IFNA1 IFNG IL2 IL2RA
17
Show member pathways
11.45 GZMB IFNG IL2 IL2RA
18 11.41 IFNG IL2 IL2RA
19 11.2 IFNG IL2 IL2RA
20 11.18 IFNG IL15 IL7
21 11.08 IFNG IL2 IL2RA
22 11.03 IFNG IL15 IL2 IL7
23 11 GZMB IFNG IL15 IL2 IL2RA IL7
24
Show member pathways
10.96 GZMB IFNG IL15 IL2 IL2RA

GO Terms for Cutaneous T Cell Lymphoma

Biological processes related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.89 IFNG IL15 IL2 IL7 TGFBR1
2 inflammatory response GO:0006954 9.8 CCR4 HDAC9 IL15 IL2RA TNFRSF8
3 humoral immune response GO:0006959 9.61 IFNA1 IFNG IL7
4 positive regulation of interleukin-17 production GO:0032740 9.51 IL15 IL2
5 positive regulation of isotype switching to IgG isotypes GO:0048304 9.48 IFNG IL2
6 regulation of defense response to virus by host GO:0050691 9.46 IFNG IL15
7 negative regulation of lymphocyte proliferation GO:0050672 9.37 IL2 IL2RA
8 positive regulation of T cell differentiation GO:0045582 9.33 IL2 IL2RA IL7
9 positive regulation of tissue remodeling GO:0034105 9.32 IL15 IL2
10 regulation of T cell homeostatic proliferation GO:0046013 9.26 IL2 IL2RA
11 positive regulation of T cell proliferation GO:0042102 9.26 IFNG IL15 IL2 IL2RA
12 immune response GO:0006955 9.17 CCR4 IFNG IL15 IL2 IL2RA IL7

Molecular functions related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.13 IFNA1 IL15 IL7
2 cytokine activity GO:0005125 9.02 IFNA1 IFNG IL15 IL2 IL7

Sources for Cutaneous T Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....